Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC

NCT07041788 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Cancer

Interventions

DRUG: Iparomlimab and Tuvonralimab Injection

Sponsor

Second Affiliated Hospital of Nanchang University

Collaborators

[object Object]